Rigel Pharmaceuticals (RIGL) Total Liabilities (2016 - 2025)
Rigel Pharmaceuticals has reported Total Liabilities over the past 16 years, most recently at $122.1 million for Q4 2025.
- For Q4 2025, Total Liabilities fell 24.01% year-over-year to $122.1 million; the TTM value through Dec 2025 reached $122.1 million, down 24.01%, while the annual FY2025 figure was $122.1 million, 24.01% down from the prior year.
- Total Liabilities for Q4 2025 was $122.1 million at Rigel Pharmaceuticals, down from $124.9 million in the prior quarter.
- Over five years, Total Liabilities peaked at $160.7 million in Q4 2024 and troughed at $122.1 million in Q4 2025.
- A 5-year average of $142.4 million and a median of $143.7 million in 2022 define the central range for Total Liabilities.
- Biggest five-year swings in Total Liabilities: soared 112.28% in 2021 and later decreased 24.01% in 2025.
- Year by year, Total Liabilities stood at $137.0 million in 2021, then rose by 7.99% to $147.9 million in 2022, then dropped by 1.37% to $145.9 million in 2023, then grew by 10.16% to $160.7 million in 2024, then dropped by 24.01% to $122.1 million in 2025.
- Business Quant data shows Total Liabilities for RIGL at $122.1 million in Q4 2025, $124.9 million in Q3 2025, and $124.8 million in Q2 2025.